hCAP18 Levels and Vitamin D Deficiency in Chronic Kidney Disease

Mass General Brigham logo

Mass General Brigham

Status

Withdrawn

Conditions

Chronic Kidney Disease
Vitamin D Deficiency

Treatments

Drug: Calcitriol
Drug: Ergocalciferol

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT01026363
1K23DK081677 (U.S. NIH Grant/Contract)
2009-P-001050/1

Details and patient eligibility

About

The human immune system produces a protein called hCAP18 (also known as LL-37 or cathelicidin). This protein is believed to help the body to fight infections. Studies suggest that vitamin D may important in the production of hCAP18. This study is designed to test the ability of two different forms of vitamin D to affect levels of hCAP18. Vitamin D and hCAP18 levels will be measured during an initial visit. Individuals who are vitamin D deficient will be randomly assigned to receive one of two forms of vitamin D for two weeks. After this, follow-up levels will be measured.

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age 18-80
  • Chronic Kidney Disease stage 3-4 (estimated glomerular filtration rate 15-60 ml/min)

Exclusion criteria

  • 6 month history of hypercalcemia, hyperphosphatemia, or nephrolithiasis
  • use of active vitamin D analog within 30 days
  • functioning renal transplant
  • Symptoms of active infection
  • Granulomatous disorders

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

0 participants in 2 patient groups

ergocalciferol
Experimental group
Description:
Ergocalciferol intervention arm
Treatment:
Drug: Ergocalciferol
calcitriol
Experimental group
Description:
calcitriol intervention arm
Treatment:
Drug: Calcitriol

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems